BEAM

#1661
Beam Therapeutics Inc. Common Stock
30.30 USD
+0.40%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
30.30
30.30
Rango anual
15.35
36.44
Cambio diario
+0.40%
Variación mensual
+17.90%
Variación en los últimos 6 meses
+18.08%
Cambio anual
+80.57%
Cierres anteriores
30.18
Abrir
30.30
Bid
Ask
Mínimo
30.30
High
30.30
Volumen
118
Ver el calendario completo

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 3.09 B
  • Employee 511
  • Founded 2017
  • CEO John Evans
  • Website www.beamtx.com
  • Headquarter Delaware, United States
  • FIGI BBG00KXC8646
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-34.22
Relación precio/flujo de caja
19.62

Beam Therapeutics Inc

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

Noticias